WORLD FIRST: PATIENT RECEIVES HIGH-RISK THERAPY TO MAKE CELLS YOUNG AGAIN

Summary from the TLDR newsletter

US-based biotechnology company Life Biosciences has dosed its first patients with an experimental therapy designed to reverse age-related vision loss. The treatment aims to turn back aging by activating three genes in nerves that do not naturally regenerate. The hope is that a single injection of the gene therapy, along with several weeks of antibiotics, can preserve or even restore vision. The genes are controlled by a genetic switch that only turns on when patients take the antibiotic, allowing for some level of control. The study will follow participants for at least five years.